"Pyrimidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.
Descriptor ID |
D011744
|
MeSH Number(s) |
D03.383.742.698
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidinones".
This graph shows the total number of publications written about "Pyrimidinones" by people in this website by year, and whether "Pyrimidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2004 | 2 | 2 | 4 |
2005 | 1 | 0 | 1 |
2006 | 2 | 0 | 2 |
2009 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
2017 | 3 | 4 | 7 |
2018 | 1 | 9 | 10 |
2019 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrimidinones" by people in Profiles.
-
Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic. Arch Endocrinol Metab. 2021 Nov 01; 65(2):242-247.
-
Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Comb Chem High Throughput Screen. 2021; 24(3):441-454.
-
Pyrexia by COVID-19 in a patient treated with dabrafenib/trametinib therapy. J Dermatol. 2021 Feb; 48(2):e122-e123.
-
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019 Oct; 28(10):827-833.
-
AZD1775 plus chemoradiotherapy for pancreatic cancer. Lancet Oncol. 2019 09; 20(9):e472.
-
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019 06; 25(6):941-946.
-
Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharm Pat Anal. 2018 Nov; 7(6):249-257.
-
Platelet factor 4 promotes rapid replication and propagation of Dengue and Japanese encephalitis viruses. EBioMedicine. 2019 Jan; 39:332-347.
-
An inhaled "bifunctional" dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. Eur Respir J. 2018 11; 52(5).
-
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018 11; 52(5).